Maze Therapeutics, Inc. Common Stock (MAZE) is a publicly traded Healthcare sector company. As of May 21, 2026, MAZE trades at $25.03 with a market cap of $1.36B and a P/E ratio of -9.98. MAZE moved +2.37% today. Year to date, MAZE is -35.21%; over the trailing twelve months it is +147.58%. Its 52-week range spans $6.71 to $53.65. Analyst consensus is strong buy with an average price target of $63.50. Rallies surfaces MAZE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Maze Therapeutics Secures $150M Financing to Fund Pipeline Through 2029: Maze Therapeutics offered 5.54 million shares at $23.50 and 850,000 pre-funded warrants at $23.499, raising $150 million in gross proceeds. The company will allocate net proceeds to advance Phase 2 assets MZE829 and MZE782 and expects cash to fund operations into 2029.
| Metric | Value |
|---|---|
| Price | $25.03 |
| Market Cap | $1.36B |
| P/E Ratio | -9.98 |
| EPS | $-2.48 |
| Dividend Yield | 0.00% |
| 52-Week High | $53.65 |
| 52-Week Low | $6.71 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $20.00M |
| Net Income | $-122.54M |
| Gross Margin | 0.00% |
12 analysts cover MAZE: 0 strong buy, 12 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $63.50.